The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series of AGC kinases, is universally active in MM, and plays pivotal roles in cell...

Full description

Bibliographic Details
Main Authors: Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi, Yoko Taminishi-Katsuragawa, Haruya Okamoto, Shusuke Yasuda, Yuka Kawaji-Kanayama, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Toshiyuki Sakai, Junya Kuroda
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:International Journal of Molecular Sciences
Subjects:
AKT
gene set enrichment analysis
mTOR
multiple myeloma
MYC
RSK2
Online Access:https://www.mdpi.com/1422-0067/23/6/2919

Internet

https://www.mdpi.com/1422-0067/23/6/2919

Similar Items